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Across many countries in the world, advanced heart failure patients who are eligible for a heart 
transplant face the same dilemma: there are not enough donor hearts available for all. The 
current next-best alternative to a heart transplant is the surgical implantation of a left ventricular 
assist device (LVAD). Although the purpose of the LVAD is to relieve the overloaded left 
ventricle of heart failure patients and restore a normal cardiac output, patients have presented 
with high levels of stroke gastrointestinal bleeding and right-heart failure. One potential reason 
for this increased risk is the continuous flow of the implanted LVAD. As a result, the majority 
of LVAD patients do not have a palpable pulse (Purohit et al., 2018), creating a unique arterial 
biology in these humans (Castagna et al., 2017). Perhaps surprising is the superior health 
outcome of patients supported with continuous-flow (CF) compared with pulsatile-flow 
LVADs. In addition, the reduced/absent pulsatility in these CF-LVAD patients (see figure 1.) 
enables the investigation of unique arterial physiology and cardiovascular regulation, which 
has already revealed some unexpected observations. For example, continuous-flow patients 
appear to have a higher sympathetic activity (Cornwell et al., 2015), and suffer complications 
above a low systolic blood pressure  of ~100 mmHg, atypical of  non-LVAD populations in 
whom hypertension (>140 mmHg) is a predictor of stroke (Pinsino et al., 2019). Thus, the 
medical debate whether continuous flow is truly better for the health of advanced heart failure 
patients also necessitates a more generic, fundamental discussion into ‘normal’ arterial 
physiology & health. The comprehensive study investigating the detailed cardiovascular 
response and adaptations to drastically altered haemodynamics in heart failure, with and 
without LVAD support, at rest, during physical activity and in combination with cardiovascular 
acting medication, is essential. This unique area of research presents an opportunity to 
significantly increase our fundamental physiological understanding of the interaction between 
cardiac dynamics (volume, force, ejection pattern) and arterial regulation (flow, blood pressure, 
sympathetic activity, endothelial function, pulsatility). Therefore, the symposium entitled 
“Bionic women and men – Physiology lessons from implantable cardiac devices” held at the 
2019 Annual Meeting of The Physiological Society in Aberdeen, UK, brought together 
clinicians and scientists from a previous CrossTalk debate (Cornwell et al., 2019; Stöhr et al., 
2019) to review the current knowledge of LVAD patients and identify outstanding questions 
in the field. In total, four presentations were given and each of them have been published as 
symposium reports in this edition of Experimental Physiology.  
Presentation 1: Cardiovascular lessons from heart failure patients implanted with left 
ventricular assist devices (Stöhr et al., 2020).  
This talk introduced the clinical background to LVAD therapy and highlighted the different 
clinical outcomes between the HeartMate II (HM II) and HeartMate 3 (HM3) pumps as well 
as the role of ‘pulsatility’ in the human circulation. Several hypotheses were proposed based 
on the current discrepancies between the physiology of LVAD patients and our long-held 
understanding of the same physiology in other populations.  
Presentation 2: Arterial Stiffness in Heart Failure Patients Implanted with Left Ventricular 
Assist Devices (McDonnell et al., 2020).  
In this talk, Dr McDonnell presented the results from a recent investigation by the ‘HIT-LVAD’ 
team, revealing that aortic stiffness does not increase in all LVAD patients, however, in those 
patients who had an increased aortic stiffness, these patients presented with a greater 
prevalence of stroke, gastrointestinal bleeding, pump thrombosis and death. 
Presentation 3: Right ventricular dysfunction in patients implanted with left ventricular assist 
devices (Kanwar et al., 2020). 
Due to the fact that a significant proportion of HM II and HM3 patients experience right-sided 
failure after LVAD implantation, Dr Kanwar presented the aetiology of right-heart failure and 
discussed potential mechanisms linking LVAD support to pulmonary hypertension. 
Presentation 4: Cardiovascular, cerebrovascular and exercise responses among patients 
supported with left ventricular assist devices (Buchanan et al., 2020). 
Finally, as a hallmark of heart failure is a reduced exercise capacity, Dr Cornwell explained 
(through presentation of unique pressure-volume data) why LVAD patients still have a limited 
exercise capacity despite a restored cardiac output at rest. Furthermore, he discussed the current 
knowledge on cerebral autoregulation in LVAD patients and highlighted the link between 
sympathetic nerve activity and stroke. 
 
Keep your finger on the pulse! 
Several important conclusions can be drawn from this symposium. First, it is essential to 
characterise the true flow dynamics of HM II and HM3 patients across the whole circulation, 
including the microcirculation. Since the HM3 LVAD produces an ‘artificial pulse’, describing 
its presence (or absence) across the circulation of these patients is essential. Such research will 
reveal the true blood flow dynamics that LVAD patients are exposed to and will assist in 
improving our general understanding of the transmission of haemodynamics (including 
pulsatility) from the heart to the end-organ. Second, the role of arterial stiffness –an 
independent predictor of cardiovascular risk in numerous populations – deserves urgent 
attention. The differential changes in aortic stiffness whilst exposed to continuous flow is a 
conundrum that may have major implications for our understanding of arterial stiffness in the 
general population. Third, understanding the mechanisms of right heart failure in LVAD 
patients will likely improve our current understanding of right-heart disease in many other 
conditions. Finally, more research is required into exercise limitations in LVAD patients, as 
well as the neurological autoregulatory capacity of the brains of LVAD patients implanted with 
different pumps. 
Collectively, the “Bionic Women and Men” symposium highlights that the role of pulsatility 
remains a contentious issue and that other physiological factors must be considered to truly 
understand cardiovascular risk in this unique patient group. Importantly, a patient’s individual 
arterial flow pulsatility will interrelate with their specific blood pressure, arterial stiffness, 
blood volume distribution and peripheral oxygen consumption to determine their overall 
health. Consequently, to improve our understanding of LVAD physiology, and extend this 
unique insight to general principles in physiology, keep your finger on the pulse! 
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Figure 1. Brain blood flow in healthy individuals (left) and advanced heart failure patients 
implanted with a continuous-flow left ventricular assist device (LVAD, right). 
